electroCore Announces Leadership Changes
electroCore, Inc., a prominent player in bioelectronic medicine, has made noteworthy leadership changes that signal a strategic shift for the company. The board has confirmed that Peter Cuneo will step down from his role, and Thomas J. Errico, MD, will take over as the new Chairman of the Board. This change is aimed at enhancing governance and steering the company through its next phase of innovation and growth in health technologies.
Farewell to Peter Cuneo
Throughout his tenure, Peter Cuneo has made significant contributions to electroCore, offering invaluable counsel and guidance since he joined the Board in 2020. Under his tenure as Chairman, he played a pivotal role in the company's turnaround and has consistently advocated for the interests of shareholders. Dan Goldberger, CEO of electroCore, expressed heartfelt gratitude towards Mr. Cuneo, recognizing his dedication and expertise that helped forge a new path for the company. Following his departure, Mr. Cuneo will remain involved with electroCore as a strategic advisor.
Welcome Thomas J. Errico, MD
Dr. Thomas Errico, a co-founder of electroCore, is highly regarded for his deep understanding of the company's mission and vision. He has previously served as the Chairman of the Nominating and Governance Committee, where his insights have shaped the company's governance policies. Mr. Goldberger looks forward to Dr. Errico's leadership, highlighting his commitment to not only the company but also its shareholders. Errico's background in medicine and his advocacy for innovative health solutions position him well to lead the board.
About electroCore, Inc.
electroCore, Inc. specializes in developing bioelectronic technologies aimed at improving health and wellness through non-invasive methods. Their flagship products, gammaCore and Quell, utilize advanced neuromodulation techniques to alleviate chronic pain conditions. Additionally, the company offers personal wellness devices that leverage bioelectronic technologies to enhance general health and human performance.
Company Vision and Future Prospects
The leadership transitions at electroCore are set against a backdrop of ongoing strategic initiatives. Experts anticipate that under Errico's guidance, the company will continue to push the envelope in the bioelectronic medicine space, enhancing accessibility and efficiency for their groundbreaking products. The organization aims to leverage strategic partnerships to bolster its market presence and expand its product offerings further.
Contact Information
For inquiries, investors can reach out to the investor relations team at electroCore by calling (973) 302-9253 or emailing investors@electrocore.com.
Frequently Asked Questions
Who has been appointed as the new Chairman of electroCore?
Thomas J. Errico, MD, has been elected as the new Chairman of the Board at electroCore.
What was the significance of Peter Cuneo's tenure at electroCore?
Peter Cuneo provided crucial leadership and guidance during his time on the Board and notably during his role as Chairman, facilitating the company's turnaround.
How long has electroCore been in operation?
electroCore, Inc. has been operational since its establishment, focusing on bioelectronic medicine.
What products does electroCore offer?
electroCore offers products such as gammaCore for chronic pain and wellness devices like Quell, which utilize bioelectronic technologies.
How can investors get in touch with electroCore for inquiries?
Investors can contact electroCore at (973) 302-9253 or through their investor email at investors@electrocore.com.
